新辅助FOLFIRINOX后切除胰腺癌辅助化疗的评估
这项国际多中心回顾性队列研究纳入520例接受至少2周期新辅助FOLFIRINOX后切除的非转移性胰腺癌患者,评估辅助化疗与总生存的关系。总体辅助化疗与未辅助化疗无生存差异,但淋巴结阳性患者辅助化疗与生存改善相关,淋巴结阴性患者无获益。
要点
- 总体辅助化疗与未辅助化疗中位OS均为29个月,无生存差异。
- 淋巴结阳性患者辅助化疗中位OS 26 vs 13个月,多变量HR 0.41。
- 淋巴结阴性患者辅助化疗无生存获益,多变量HR 0.85。
核心结论
- 新辅助FOLFIRINOX后切除胰腺癌,辅助化疗仅与病理证实的淋巴结阳性患者生存改善相关。
研究设计与样本
- 国际多中心回顾性队列研究,2012年1月1日至2018年12月31日,纳入31个中心19个国家的520例患者。
- 纳入至少2周期新辅助FOLFIRINOX后切除的非转移性胰腺癌患者,排除院内死亡或术后3个月内死亡者。
主要发现
- 520例患者中343例(66.0%)接受辅助化疗,其中68例(19.8%)接受FOLFIRINOX,201例(58.6%)接受吉西他滨为基础化疗。
关键数值与推荐
- 中位新辅助FOLFIRINOX周期数为6(IQR 5-8)。
- 诊断后中位OS为38个月(95%CI 36-46个月),术后中位OS为31个月(95%CI 29-37个月)。
- 多变量分析中仅淋巴结分期与辅助治疗的交互项有统计学意义。
临床怎么用
- 对于新辅助FOLFIRINOX后切除的胰腺癌患者,辅助化疗决策可考虑淋巴结病理状态。
- 淋巴结阳性患者可能从辅助化疗中获益,淋巴结阴性患者辅助化疗未显示生存优势。
局限性
- 回顾性队列研究设计,可能存在选择偏倚和混杂。
- 辅助化疗方案异质,包括FOLFIRINOX、吉西他滨为基础、卡培他滨及联合或其他药物。
- 作者建议未来开展随机研究以确认该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. OBJECTIVE: To assess the association of adjuvant chemotherapy with overall survival (OS) in patients after pancreatic cancer resection and neoadjuvant FOLFIRINOX treatment. DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, retrospective cohort study was conducted from January 1, 2012, to December 31, 2018. An existing cohort of patients undergoing resection of pancreatic cancer after FOLFIRINOX was updated and expanded for the purpose of this study. All consecutive patients who underwent pancreatic surgery after at least 2 cycles of neoadjuvant FOLFIRINOX chemotherapy for nonmetastatic pancreatic cancer were retrospectively identified from institutional databases. Patients with resectable pancreatic cancer, borderline resectable pancreatic cancer, and locally advanced pancreatic cancer were eligible for this study. Patients with in-hospital mortality or who died within 3 months after surgery were excluded. EXPOSURES: The association of adjuvant chemotherapy with OS was evaluated in different subgroups including interaction terms for clinicopathological parameters with adjuvant treatment in a multivariable Cox model. Overall survival was defined as the time starting from surgery plus 3 months (moment eligible for adjuvant therapy), unless mentioned otherwise. RESULTS: We included 520 patients (median [interquartile range] age, 61 [53-66] years; 279 [53.7%] men) from 31 centers in 19 countries. The median number of neoadjuvant cycles of FOLFIRINOX was 6 (interquartile range, 5-8). Overall, 343 patients (66.0%) received adjuvant chemotherapy, of whom 68 (19.8%) received FOLFIRINOX, 201 (58.6%) received gemcitabine-based chemotherapy, 14 (4.1%) received capecitabine, 45 (13.1%) received a combination or other agents, and 15 (4.4%) received an unknown type of adjuvant chemotherapy. Median OS was 38 months (95% CI, 36-46 months) after diagnosis and 31 months (95% CI, 29-37 months) after surgery. No survival difference was found for patients who received adjuvant chemotherapy vs those who did not (median OS, 29 vs 29 months, univariable hazard ratio [HR], 0.99; 95% CI, 0.77-1.28; P = .93). In multivariable analysis, only the interaction term for lymph node stage with adjuvant therapy was statistically significant: In patients with pathology-proven node-positive disease, adjuvant chemotherapy was associated with improved survival (median OS, 26 vs 13 months; multivariable HR, 0.41 [95% CI, 0.22-0.75]; P = .004). In patients with node-negative disease, adjuvant chemotherapy was not associated with improved survival (median OS, 38 vs 54 months; multivariable HR, 0.85; 95% CI, 0.35-2.10; P = .73). CONCLUSIONS AND RELEVANCE: These results suggest that adjuvant chemotherapy after neoadjuvant FOLFIRINOX and resection of pancreatic cancer was associated with improved survival only in patients with pathology-proven node-positive disease. Future randomized studies should be conducted to confirm this finding.
引用
- van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncol. 2020. PMID: 32910170. doi:10.1001/jamaoncol.2020.3537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。